Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 679-683

  Anthias, C ^a   Dignan, F L ^a   Morilla, R ^a,b   Morilla, A ^a,b   Ethell, M E ^a   Potter, M N ^a   Shaw, B E ^a,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

allo SCT; AML; flow cytometry; MRD

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; FLOW CYTOMETRY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPARAMETRIC FLOW CYTOMETRY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84900303568     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.9     Document Type: Article

References (29)

1. Cornelissen JJ, Van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-Aged adults: Benefits for whom? Blood 2007; 109: 3658-3666
2. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-Analysis of prospective clinical trials. JAMA 2009; 22: 2349-2361
3. Suciu S, Mandelli F, De Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 4: 1232-1240
4. Appelbaum FR. Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). Best Pract Res Clin Haematol 2008; 1: 85-92
5. Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007; 109: 2264-2265
6. Schlenk RF, Dohner K, Krauter J. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918
7. Dezern AE, Sung A, Kim S, Smith B Douglas, Karp Judith E, Gore Steven D et al. Role of allogeneic transplantation for flt3/itd acute myeloid leukemia: Outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011; 17: 1404-1409
8. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006; 10: 1783-1789
9. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-3085
10. Laane E, Derolf AR, Björklund E, Mazur J, Everaus H, Söderhäll S et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006; 91: 833-836
11. San Miguel JF, Martínez A, Macedo A, Vidriales MB, Löpez-Berges C, Gonzälez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470
12. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W et al. New score predicting for prognosis in PML-RARA, AML1-ETO, or CBFBMYH11 acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746-2755
13. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952
14. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23: 379-390
15. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European Leukemia Net study. J Clin Oncol 2009; 27: 5195-5201
16. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341
17. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. GIMEMA acute leukemia working party. cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254-266
18. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-Associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003; 88: 646-653
19. Al-Mawali A, Gillis D, Hissaria P, Lewis I. Incidence, sensitivity, and specificity of leukemia-Associated phenotypes in acute myeloid leukemia using specific fivecolor multiparameter flow cytometry. Am J Clin Pathol 2008; 129: 934-945
20. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncology 2011; 29: 1190-1197
21. Walter R, Buckley S, Pagel J, Wood B, Storer B, Sandmaier B et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813-1821
22. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 2013; 48: 1415-1420
23. Diez-Campelo JA, Perez-Simon J, Perez M, Alcoceba J, Richtmon B, Vidriales B et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009; 84: 149-152
24. Miyazaki T, Fujita H, Fujimaki K, Hosoyama T, Watanabe R, Tachibana T et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res 2012; 36: 998-1003
25. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951
26. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365
27. Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944-4951
28. Sproat L, Bolwell B, Rybicki L, Tench S, Chan J, Kalaycio M et al. Effect of postremission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. Leuk Lymphoma 2010; 51: 1699-1704
29. McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 2011; 35: 757-761.